Literature DB >> 2462571

Dose-response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin.

A M Suikkari1, V A Koivisto, R Koistinen, M Seppälä, H Yki-Järvinen.   

Abstract

We previously demonstrated that supraphysiological insulin concentrations reduced the plasma 34K insulin-like growth factor-binding protein (IGF-BP) concentrations in humans. In this study we examined whether physiological changes in plasma insulin concentrations regulate IGF-BP and, if so, whether the regulation is influenced by race, glucose tolerance, or rate of glucose metabolism. For these purposes we 1) analyzed the relationship between fasting plasma insulin and IGF-BP concentrations in 2 racial groups (23 caucasians and 35 southwestern American Indians), 2) measured the response of plasma IGF-BP to oral glucose in 20 normal subjects, and 3) determined the dose-response characteristics of plasma IGF-BP to glucose and insulin in 23 normal subjects at 4 different insulin and glucose concentrations. The fasting plasma insulin concentration was inversely related to the plasma IGF-BP concentration in both the caucasian and Indian groups (P less than 0.0001). In the caucasian group the mean plasma IGF-BP concentration was higher [15 +/- 4 (+/- SE) micrograms/L] than in the Indian group (8 +/- 2 micrograms/L; P less than 0.05). This difference was independent of race and glucose tolerance, and it could be explained by lower plasma insulin concentrations in the caucasian (387 +/- 50 pmol/L) than in the Indian group (215 +/- 43 pmol/L; P less than 0.001). After oral glucose administration, the insulin concentration (423 +/- 72 pmol/L) was maximal 30 min after glucose treatment, and significant suppression of the IGF-BP concentration occurred at 90 min. Analysis of the dose-response curves revealed maximal suppression of IGF-BP at about 1150 pmol/L insulin, and half-maximal suppression at about 290 pmol/L. The plasma glucose concentration or the rate of glucose metabolism had no effect on the IGF-BP concentration. These data suggest that insulin is a major regulator of plasma IGF-BP concentrations under physiological conditions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2462571     DOI: 10.1210/jcem-68-1-135

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Growth factors in the ovary.

Authors:  G Giordano; A Barreca; F Minuto
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

Review 2.  Regulation of gene expression by insulin.

Authors:  R M O'Brien; D K Granner
Journal:  Biochem J       Date:  1991-09-15       Impact factor: 3.857

Review 3.  Somatomedin-binding proteins: what role do they play in the growth process?

Authors:  S Cianfarani; J M Holly
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

4.  The gene encoding human low-molecular weight insulin-like growth-factor binding protein (IGF-BP25): regional localization to 7p12-p13 and description of a DNA polymorphism.

Authors:  T Alitalo; K Kontula; R Koistinen; K Aalto-Setälä; M Julkunen; O A Jänne; M Seppälä; A de la Chapelle
Journal:  Hum Genet       Date:  1989-11       Impact factor: 4.132

5.  Disturbed synthesis of insulinlike growth factor I and its binding proteins may influence renal function changes in liver cirrhosis.

Authors:  C M Fernández-Rodriguez; I Prada; A Andrade; M Moreiras; R Guitián; R Aller; J L Lledó; G Cacho; J Quiroga; J Prieto
Journal:  Dig Dis Sci       Date:  2001-06       Impact factor: 3.199

6.  Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice.

Authors:  K Rajkumar; M Krsek; S T Dheen; L J Murphy
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

7.  Aerobic exercise training increases circulating insulin-like growth factor binding protein-1 concentration, but does not attenuate the reduction in circulating insulin-like growth factor binding protein-1 after a high-fat meal.

Authors:  Steven J Prior; Nathan T Jenkins; Josef Brandauer; Edward P Weiss; James M Hagberg
Journal:  Metabolism       Date:  2011-08-26       Impact factor: 8.694

8.  Elevated plasma insulin-like growth factor binding protein-1 levels in type 1 (insulin-dependent) diabetic patients with peripheral neuropathy.

Authors:  S R Crosby; C Tsigos; C D Anderton; C Gordon; R J Young; A White
Journal:  Diabetologia       Date:  1992-09       Impact factor: 10.122

9.  Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men.

Authors:  M S Lewitt; A Hilding; C-G Ostenson; S Efendic; K Brismar; K Hall
Journal:  Diabetologia       Date:  2008-05-22       Impact factor: 10.122

10.  Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus.

Authors:  P D Zenobi; S E Jaeggi-Groisman; W F Riesen; M E Røder; E R Froesch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.